CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Purple Biotech Ltd   (PPBT)
Other Ticker:  
 


Purple Biotech Ltd 's ROA from the fourth quarter of 2022 to the fourth quarter of 2021 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Purple Biotech Ltd 's ROA in the fourth quarter of 2022?
Purple Biotech Ltd achieved a return on average assets (ROA) of 45.84 % in its fourth quarter of 2022, this is above PPBT's average return on assets of 35.5%.
Purple Biotech Ltd assets over the 12 months ending in its fourth quarter of 2022 are valued at $47 million

ROA has improved compared to 34.75% in the third quarter of 2022, due to net income growth.

However, within the Healthcare sector 27 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2022 from to 92.

What is ROA?


Return On Assets (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Total Assets Change -32.38 % -32.38 % -32.38 % -32.38 % -15.89 %
Y / Y Net Income Change 17.83 % - - - -34.22 %
Net Income (TTM) in million 22 18 18 18 18
Return On Assets (TTM) 45.84 % 34.75 % 31.39 % 28.63 % 26.31 %
PPBT's Total Ranking # 92 # # # # 217
Total Assets (TTM) in million 47 47 47 47 70
Seq. Total Assets Change 0 % 0 % 0 % -32.38 % 0 %
Seq. Net Income Change - - - - -

PPBT's 5 Years Annual ROA >> Back to PPBT Management Effectiveness >> Compare PPBT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 17
Sector # 28
Overall # 89

Return On Assets Statistics
High Average Low
40.04 %
35.5 %
26.31 %
(Dec 31 2019)   (Dec 31 2021)


Financial Statements
Purple Biotech Ltd 's Assets $ 47 million PPBT's Balance sheet
Purple Biotech Ltd 's Income $ 22 million Quarterly PPBT's Income Statement
PPBT's Income by Division See PPBT's Income by Division



Annual Return On Assets (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
Y / Y Total Assets Change -32.38 % -15.89 % 482.01 % -1.45 % -
Total Assets in million 47 70 83 14 15
Y / Y Net Income Change 17.83 % -34.22 % 376.4 % 5.82 % -
Net Income in million 22 18 28 6 6
Return On Assets 45.84 % 26.31 % 33.64 % 41.09 % 38.27 %

PPBT's 5 Years Annual ROA >> Back to PPBT Management Effectiveness >> Compare PPBT ROA to its Competitors



Comment on PPBT's ROA in the fiscal year ending 2022
In the fiscal year 2022 ROA improved to 45.84 % compared to prior year, due to annual net income growth of 17.83 % to $21.76 million, and due to decline of value in Purple Biotech Ltd 's assets by -32.38 % to $47.47 million, compared to $47.47 a year before.


More Return On Assets Ratios
PPBT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PPBT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Roa for PPBT's Competitors
Roa for Purple Biotech Ltd 's Suppliers
Return On Assets for PPBT's Customers

You may also want to know
PPBT's Roi PPBT's Inventory Turnover Ratio PPBT's Growth Rates PPBT's Dividend Comparisons
PPBT's Profitability Ratios PPBT's Asset Turnover Ratio PPBT's Dividend Growth
PPBT's Roe PPBT's Valuation Ratios PPBT's Financial Strength Ratios PPBT's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2022, within Healthcare Sector ROA
Catalyst Biosciences Inc   119.62 %
Glucotrack Inc   113.54 %
Galmed Pharmaceuticals Ltd   107.88 %
Chimerix inc   99.48 %
Therapeuticsmd Inc   88.90 %
Biovie Inc   80.11 %
Acelrx Pharmaceuticals Inc  75.95 %
Molecular Templates inc   71.29 %
Ocuphire Pharma Inc   70.19 %
Gamida Cell Ltd   67.32 %
First Wave Biopharma Inc   59.30 %
Kiniksa Pharmaceuticals Ltd   53.88 %
Chemomab Therapeutics Ltd   52.51 %
Biomx Inc   50.44 %
Dariohealth Corp   48.76 %
Shockwave Medical Inc   45.20 %
Redhill Biopharma Ltd   45.11 %
Molecular Partners Ag  44.94 %
Sensus Healthcare Inc   43.73 %
Check cap Ltd   42.05 %
Intercept Pharmaceuticals inc   41.95 %
Purple Biotech Ltd   39.84 %
Fusion Pharmaceuticals Inc   38.02 %
Harmony Biosciences Holdings inc   31.75 %
Moderna Inc   31.68 %
Assertio Holdings inc   31.36 %
Dynavax Technologies Corporation  29.16 %
Zymeworks Inc   28.45 %
Point Biopharma Global Inc   28.26 %
Alpha Tau Medical ltd   28.10 %

Date modified: 2023-03-23T13:12:32+00:00


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com